{"disease":{"id":"multiple-sclerosis-ms","name":"multiple sclerosis ms"},"drugs":{"marketed":[{"drug_id":"fty720","indication_name":"Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FTY720","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)","drug_class":"Sphingosine-1-phosphate receptor modulator; Immunomodulator","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03456206","title":"Chronic Inflammatory Disease, Lifestyle and Risk of Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":57053,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT06705608","title":"Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study","phase":"","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT04907305","title":"Next-Gen MS: Feed-forward PRO Data for MS Research","phase":"","overall_status":"TERMINATED","enrollment_count":1594,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":false},{"nct_id":"NCT05058729","title":"MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study","phase":"","overall_status":"COMPLETED","enrollment_count":1507,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07225504","title":"A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03316404","title":"Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response","phase":"","overall_status":"COMPLETED","enrollment_count":1168,"lead_sponsor_name":"DxTerity Diagnostics","has_results":false},{"nct_id":"NCT04130997","title":"An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1100,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01633112","title":"MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1064,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT03387670","title":"Multiple Sclerosis-Simvastatin Trial 2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":964,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03523858","title":"A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":927,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03961204","title":"Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":662,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT02921035","title":"Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)","phase":"","overall_status":"COMPLETED","enrollment_count":594,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT03277261","title":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03277248","title":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":545,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04593927","title":"Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients","phase":"","overall_status":"COMPLETED","enrollment_count":451,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06541626","title":"Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06700343","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":444,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02907281","title":"Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":414,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05304520","title":"A Study for Tysabri Participant Preference","phase":"","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06157086","title":"Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":302,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07222618","title":"\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07195110","title":"Prevalence of Periodontitis in Egyptian Multiple Sclerosis Patients.","phase":"","overall_status":"COMPLETED","enrollment_count":293,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04777539","title":"Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04115488","title":"Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Polpharma Biologics S.A.","has_results":true},{"nct_id":"NCT05000216","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":258,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT06733922","title":"ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07318129","title":"Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Glostrup University Hospital, Copenhagen","has_results":false},{"nct_id":"NCT03737851","title":"A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05106465","title":"A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05811416","title":"A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06869785","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":196,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02587065","title":"Plegridy Satisfaction Study in Participants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":193,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT07235644","title":"Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT07497126","title":"The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":169,"lead_sponsor_name":"Antalya Training and Research Hospital","has_results":false},{"nct_id":"NCT05242133","title":"Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Cinnagen","has_results":false},{"nct_id":"NCT06486779","title":"Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05197699","title":"Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study","phase":"","overall_status":"TERMINATED","enrollment_count":160,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05245344","title":"Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study","phase":"","overall_status":"UNKNOWN","enrollment_count":154,"lead_sponsor_name":"Neuromed IRCCS","has_results":false},{"nct_id":"NCT04338646","title":"Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Gérard Amarenco","has_results":false},{"nct_id":"NCT07273604","title":"Psychological Interventions for Multiple Sclerosis: Effects on Anxiety, Depression, and Cognition.","phase":"NA","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Moisés Bermúdez Hernández","has_results":false},{"nct_id":"NCT04203498","title":"Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":139,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT03972306","title":"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04926818","title":"Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":129,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03737812","title":"A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06270641","title":"Increasing Physical Activity for Adults With Multiple Sclerosis (MS)","phase":"NA","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05575843","title":"Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®","phase":"NA","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT04928716","title":"Multiple Sclerosis and Voiding Symptoms: How to Assess?","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Pierre and Marie Curie University","has_results":false},{"nct_id":"NCT05010902","title":"Pregnancy Cohort in Multiple Sclerosis (MS)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT05865405","title":"A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of California, San Francisco","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}